Clinical trial

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

NCT06395753

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-05-23

PhasePHASE2

Study timeline

Study start (actual)2024-05-23Date precision: day

Registry last updated2026-08-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Debio 4228DRUG

Sponsors & collaborators

Debiopharm International SAlead sponsor

Mapped research locations

BarcelonaSpain2 New YorkNew York, United States1 Los AngelesCalifornia, United States1 MiamiFlorida, United States1 ValenciaSpain1 SpokaneWashington, United States1 NantesFrance1 FresnoCalifornia, United States1 DijonFrance1 Clermont-FerrandFrance1 BakersfieldCalifornia, United States1 Chula VistaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06395753 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.